You are here

  • Home
  • Archive
  • Volume 10, Issue Suppl 2
  • 625 A phase 1 single ascending dose study evaluating the safety, tolerability, and pharmacodynamic effects of MDK-703, an IL-7 mimetic with extended half-life

Citation Tools

Article menu

Download PDFPDF

Regular and Young Investigator Award Abstracts
Clinical Trials In Progress
625 A phase 1 single ascending dose study evaluating the safety, tolerability, and pharmacodynamic effects of MDK-703, an IL-7 mimetic with extended half-life
Free

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Friend R, Baxter B, Park IA, et al
625 A phase 1 single ascending dose study evaluating the safety, tolerability, and pharmacodynamic effects of MDK-703, an IL-7 mimetic with extended half-life
Journal for ImmunoTherapy of Cancer 2022;10:doi: 10.1136/jitc-2022-SITC2022.0625